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Abstract
Objectives: High body mass index (BMI) is associated with poorer survival in child-
hood acute lymphoblastic leukemia (ALL), but the actual impact on the risk of re-
lapse still needs to be clarified. We evaluated the impact of BMI at diagnosis on the 
risk of relapse in children with ALL treated according to Nordic Society of Paediatric 
Haematology and Oncology (NOPHO) protocols.
Method: In a multicenter study, we collected data on BMI at diagnosis and outcome 
of 2558 children aged 2.0-17.9 years diagnosed between 1992 and 2016. Patients 
were divided into four groups according to International Obesity Task Force (IOTF) 
childhood BMI cut-offs: underweight, <17; healthy weight, 17-25; overweight, 25-
30; and obese, ≥30 kg/m2.
Results: In Cox multivariate regression analyses, an increased risk of relapse was ob-
served in children aged 10-17.9 years with unhealthy BMI at diagnosis (underweight haz-
ard ratio HR: 2.90 [95% confidence interval: 1.24-6.78], P = .01; overweight, HR: 1.95 
[1.11-3.43], P = .02, and obese HR: 4.32 [95% 2.08-8.97], P < .001), compared to children 
with healthy weight. BMI had no impact on relapse in children under 10 years of age.
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1  | INTRODUC TION
Today, approximately 90% of children with acute lymphoblastic 
leukemia (ALL) can be cured with modern treatment protocols.1,2 
Individualized treatment strategies are needed to address the ad-
verse outcome in high-risk subgroups. Current risk stratification is 
based on the disease characteristics at diagnosis, genetic changes in 
the leukemic cells, and early treatment response. Age is also often 
considered in risk stratification.
Adipose tissue is an active metabolic and endocrine organ. The 
amount of body fat, for which body mass index (BMI) is a surro-
gate marker, may influence the pharmacokinetics of antileukaemic 
agents, modify immunity against infections, and affect the risk 
of treatment related toxicity. BMI at diagnosis affect outcomes 
of ALL treatment and could be an important predictive factor in 
childhood ALL. Two meta-analyses studying the impact of BMI on 
outcomes concluded that high BMI at diagnosis is associated with a 
poorer overall (OS) and event-free survival (EFS) in pediatric ALL,3,4 
although both conclude that the impact of BMI on the risk of re-
lapse still needs to be clarified. Findings from earlier studies on 
the risk of relapse have reported inconsistent results, some studies 
reporting a tendency toward a higher relapse rate in overweight 
and obese children,5-7 while others found no association.8,9 One 
large study from the Children's Cancer Group found a higher risk 
of relapse in obese patients compared with non-obese children.6 In 
their study, obesity was more strongly associated with the relapse 
risk in preadolescent and adolescent patients than in younger pa-
tients. Furthermore, underweight has also been associated with a 
higher relapse risk.10
BMI may be an additional independent risk factor for adverse 
outcome to consider in risk stratification for treatment assignment 
in ALL protocols. Knowledge on the reasons for adverse outcome 
with unhealthy BMI is scarce. We hypothesized that children in ex-
treme BMI categories at diagnosis are more likely to relapse. This 
retrospective study investigated the impact of BMI at diagnosis on 




We included all children aged 2.0-17.9 years at diagnosis of ALL, be-
tween 1992 and 2016 and enrolled in the Nordic Society of Paediatric 
Hematology and Oncology (NOPHO) ALL protocols 1992, 2000, and 
2008. Surviving patients were followed until the end of December 
2017. Patients with missing data on BMI and non-protocol patients 
(acute leukemia of ambiguous lineage, Philadelphia-positive ALL, 
mature B-cell leukemia, and patients with Down syndrome) were 
excluded as well as those below 2 years old at diagnosis because 
the BMI cut-offs used in this study are defined from 2 years of age. 
The study was approved by the Regional Ethical Review Board in 
Stockholm (reference number 2018/1888-31).
2.2 | Treatment protocols
The children were treated in one of five Nordic countries (Sweden, 
Norway, Denmark, Finland, and Iceland) according to the NOPHO 
ALL1992,11,12 ALL2000,13,14 or ALL200815,16 protocols, which 
have been described in detail earlier. Patients from Lithuania 
and Estonia were included starting from July 2008 (NOPHO 
ALL2008). In brief, the risk stratification included age (for the 
two first protocols only), white blood cell (WBC) count, central 
nervous system (CNS) status, immunophenotype, and cytogenet-
ics at diagnosis and initial treatment response.13-15 The children 
were divided into non-high (ie, standard and intermediate risk) 
and high-risk groups. Patients treated according to the NOPHO 
ALL1992 protocol were classified into the high-risk group based 
on WBC count >50 × 10^9/L at diagnosis, T-cell immunophe-
notype, CNS or testicular involvement, the presence of t(4;11) 
(q21;q23) or poor response to treatment. In the NOPHO ALL2000 
protocol, the risk assignment was similar to the ALL1992 protocol, 
with the addition of any KMT2A-rearrangement, hypodiploidy, 
and t(1;19) as high-risk criteria. In the 2008 protocol, high-risk 
patients were defined as those with B-cell-precursor (BCP) ALL 
with WBC > 100 × 10^9/L at diagnosis or T-cell immunopheno-
type and MRD > 0.1% at day 29, or any patient with poor response 
(MRD > 5% on treatment day 29 or ≥0.1% day 79) or unfavorable 
cytogenetics (KMT2A rearrangement and/or hypodiploidy). CNS 
disease was defined as >5 × 10^6/L leukocytes in cerebrospinal 
fluid and leukemic blasts on cytospin or neurological symptoms 
such as cranial nerve palsy. Patients dying before response evalu-
ation during induction (induction deaths) were for the purpose 
of this study divided to non-high-risk or high-risk groups accord-
ing to their risk stratification at diagnosis. The body surface area 
(BSA) was used for dosing in all systemic chemotherapies, but a 
maximum dose of 2 mg (NOPHO ALL1992) or 2.5 mg (NOPHO 
ALL2000 and ALL2008) was applied for vincristine.
Conclusion: High BMI, and especially obesity at diagnosis, is an independent adverse 
prognostic factor for relapse in older children with ALL.
K E Y W O R D S
acute lymphoblastic leukemia, body mass index, children, obesity, survival
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2.3 | Register data
This study is based on data retrieved from the NOPHO registry. The 
registry includes prognostic risk factors at diagnosis, such as WBC 
count, immunophenotype, cytogenetics, and CNS status. Additional 
data provided were assessment of response to induction at day 29 
by morphology (NOPHO ALL1992 and ALL2000) or by minimal re-
sidual disease (MRD) (NOPHO ALL2008) and the administered risk 
group adapted treatment and follow-up data such as time of relapse, 
death, secondary malignant neoplasm (SMN), and last follow-up in 
continuous complete remission. Treatment related mortality (TRM) 
was defined as death during induction or death during first complete 
remission (DCR1).
BMI, based on registered height and weight at diagnosis, was cal-
culated and classified according to international age- and sex-adjusted 
(International Obesity Task Force, IOTF) BMI cut-offs, in our study re-
ferred to as IOTF cut-offs, set by Cole et al for thinness and the IOTF 
for overweight and obesity.17,18 The BMI classifications are based on 
smoothed sex-specific IOTF curves, which provide cut-offs corre-
sponding to BMI of <17 kg/m2 for thinness/underweight, >25 kg/m2 
for overweight and ≥30 kg/m2 for obesity at 18 years of age. The BMI 
cut-offs are tracked back to define BMI values for younger ages with 
centiles constructed using the LMS method19 based on 6 nationally 
representative data sets. The patients were classified into four groups 
using IOTF cut-offs for underweight, overweight, and obesity. BMI 
values were also transformed into standard deviation scores (SDS) for 
further analyses.20 To make the study more comparable with other 
studies, survival analyses were repeated using classification according 
to the WHO growth references. The WHO reference uses cut-offs 
based on standard deviation scores, where –2 SDS from the age-sex-
specific growth reference median is classified as underweight. The cut-
off terminology for overweight and obesity differs for children below 
and above 5 years. In children below 5 years of age, SDS between +1 
and 2 is defined as risk of overweight and over +2 SDS as overweight 
(including obesity).21 We have defined obesity as over +3 SDS in the 
younger children. In the children of 5-18 years, +1 SDS and +2 SDS are 
used to define overweight and obesity, respectively.22
2.4 | Statistical analysis
The association between BMI category and other categorical variables 
was explored using chi-square test. The primary outcome of interest 
was the risk of relapse in different weight categories. OS was defined 
as days from diagnosis until death from any cause. EFS was calculated 
from the time of diagnosis to relapse, secondary malignancy, or death 
in complete remission. Those alive and event free at the last follow-
up were also censored at that time point. Patients who underwent 
hematopoietic stem cell transplantation were censored at the date of 
transplantation. The Kaplan-Meier (KM) method was used to estimate 
the probability of cumulative incidence of relapse and OS in different 
BMI categories. Cumulative incidence of relapse was calculated and 
visualized with death and SMN as competing risks.23 Cox proportional 
hazard regression analyses were used to analyze the effect of BMI on 
the primary outcome relapse, compared to children with healthy BMI, 
but also the potential effect on OS, EFS, induction death, SMN, DCR1, 
and TRM. Multivariate Cox proportional hazard models were con-
structed adjusting for sex, age, protocol, and risk group. The linearity 
assumption of the association between log HR of relapse and BMI SDS 
entered as a continuous variable in a Cox Proportional Hazards Model 
was tested using a model with restricted cubic splines. Statistical anal-
yses were performed using SPSS version 25.0 for Windows (SPSS Inc, 




Of the 3941 children with ALL, 1383 (35%) were excluded due to 
missing BMI, most of whom (1255 patients; 91%) were treated with 
the oldest ALL protocol, NOPHO ALL1992. There were no statis-
tically significant differences in sex, age, risk group, immunophe-
notype, and CNS status at diagnosis between children with and 
without registered BMI.
Of the 2558 children included in the study cohort, 123 (4.8%) 
were classified as underweight, 2113 (82.6%) as healthy weight, 258 
(10.1%) as overweight, and 64 (2.5%) as obese, according to IOTF 
cut-offs, at the time of diagnosis (Table 1). The median age at diagno-
sis was 5.1 years (range, 2.0-17.9 years).
Overweight and obese patients were more likely to belong to the 
older age group, 10 to 17.9 years (P < .001), or to be stratified into 
the high-risk group (P = .008). There were more patients from the 
older age group in the high-risk group compared to the younger age 
group (36.8% vs 18.7%). The higher frequency for obese and over-
weight patients to be stratified into the high-risk group was not sig-
nificant when analyzing the patients in the two separate age groups 
(Table S1 and S2). There were no statistically significant differences 
in sex, immunophenotype, CNS status at diagnosis, treatment re-
sponse at end of induction, or hematopoietic stem cell transplan-
tation between the different BMI categories. The median follow-up 
time was 6.6 years (range, 5 days-23.9 years) among patients who 
were alive at last recorded follow-up.
Obese patients had significantly poorer outcomes than those 
with healthy BMI. After adjustment in multivariate Cox regression 
analyses for age, protocol, risk group, and sex, obese children had 
a tendency to higher risk of relapse (HR: 1.72, 95% CI: 0.98-3.00, 
P = .06), and a significant higher risk of death (OS; HR: 3.03, 95% CI: 
1.66-5.53, P < .001), and lower EFS (HR: 2.04, 95% CI: 1.30-3.22, 
P = .002), than healthy weight children (Table 2).
Differences in outcome between BMI categories, according to 
IOTF cut-offs, were only observed in the older children (n = 578), 
after separating the cohort into two age groups (younger age group 
2-9.9 years and older age group 10-17.9 years). No differences in 
survival, nor relapse, between the BMI categories were found in 
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the younger cohort (n = 1980). Of the older children with obesity 
39.1% (n = 9) relapsed, compared to 11.4% (n = 52) children with 
healthy BMI, 28.6% (n = 6) with underweight children and 20.8% 
(n = 16) with overweight (Table 3). In the multivariate Cox regres-
sion analyses, adjusted for age, protocol, risk group, and sex in the 
older children, obese children had a higher risk of relapse (HR: 4.32, 
95% CI: 2.08-8.97, P < .001) as well as overweight (HR: 1.95, 95% 
CI: 1.11-3.43, P = .02) and underweight children (HR: 2.90, 95% CI: 
1.24-6.78, P = .01), compared to healthy weight children (Table 2). 
The site of relapse did not differ significantly between the BMI 
categories.
In the same age group, the obese children had worse OS (HR: 
4.91, 95% CI: 2.20-11.05, P < .001) and EFS (HR: 4.00, 95% CI: 2.13-
7.54, P < .001) than healthy weight children.
Kaplan-Meier survival analysis in the older age group indicated 
statistically significant differences in the cumulative probability of 
relapse (log rank; P < .001) and the probability of OS (P < .001) be-
tween obese and healthy weight children (Figure 1A-D).
The association between BMI SDS as a continuous variable and 
the log HR for relapse in the older age group demonstrated that it is 
beneficial for both underweight and obese children to be closer to 
healthy weight (Figure 2). The association between BMI-SDs with 
relapse remained significant in the model after adjusting for age at 
diagnosis as a continuous variable.
3.2 | Events, death and toxicities
We analyzed SMN, (22 events) induction death (24 events), and 
DCR1 (43 events) in children aged 2.0-17.9 years separately in multi-
variate hazard ratio analysis adjusting for sex, age, protocol, and risk 
group. When divided into different BMI categories, the number of 
events in each group was small, but overweight and obese patients 
indicated a higher risk of SMN compared to healthy weight patients 
(HR: 4.66, 95% CI: 1.71-12.64, P = .003; HR: 11.56, 95% CI: 3.18-
42.12, P < .001, respectively, Table 2). There was no significant asso-
ciation between induction death or DCR1 and BMI categories TRM 
was reported in two (1.6%) of 123 underweight patients, 51 (2.4%) of 
2113 patients with healthy weight, 10 (3.9%) of 258 overweight, and 
four (6.3%) of 64 obese children. There was no association with risk 
of TRM in the extreme BMI categories of obese (HR: 2.43, 95% CI: 
0.87-6.76, P = .09) or underweight patients (HR: 0.82, 95% CI: 0.20-
3.38, P = .78) compared to healthy weight patients. Due to the small 
number of events for induction death, DCR1, SMN and TRM, multi-
variate Cox regression analyses stratified into younger and older age 
groups were not conclusive.
To study how the chosen international BMI cut-offs effected the 
results, the analyses were also performed using classification and cut-
offs based on WHO growth references. With WHO cut-offs, 77 (3.0%) 
were classified as underweight, 1928 (75.4%) as healthy weight, 426 
(16.7%) overweight, and 127 (5.0%) children as obese. The multivariate 
Cox regression survival analyses showed similar associations with both 
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higher risk for DCR1 (HR: 2.17, 95% CI 1.11-4.26, P = .02 and HR: 2.90, 
95% CI 1.10-7.60, P = .03), which was not statistically significant in the 
analyses using the international cut-offs.
4  | DISCUSSION
Limited evidence exists on the association between BMI and re-
lapse in children with ALL. This study demonstrates that being over-
weight or obese at diagnosis is associated with higher risk of relapse 
in adolescent ALL, treated according to Nordic leukemia protocols. 
Our results are in line with a large study from the Children's Cancer 
group that also found obesity at time of diagnosis to be an independ-
ent predictor of relapse and worse EFS in older children.6 Similarly, 
a meta-analysis concluded that overweight and obese BMI was as-
sociated with poorer OS and EFS and a tendency to increased risk of 
relapse in pediatric ALL.3
In this study, the increased risk of relapse among the extreme BMI 
categories, especially the obese patients, was the main reason for 
the poorer overall survival. In contrast to Orgel el al,24 we could not 
TA B L E  2   Univariate and multivariate hazard ratios for relapse and other events according to the IOTF BMI category





Obese vs healthy 
weight P
Overweight + obese 
vs healthy weight P
Patients aged 2.0-17.9 y
Univariate Analysis
Relapse risk 0.87 (0.56-1.63) .96 1.09 (0.75-1.58) .66 2.11 (1.21-3.68) .009 1.27 (0.92-1.75) .14
Overall survival 0.61 (0.23-1.65) .33 1.38 (0.84-2.27) .20 3.90 (2.14-7.07) <.001 1.86 (1.24-2.78) .003
Event-free survival 0.98 (0.61-1.58) .95 1-31 (0.96-1.78) .08 2.52 (1.61-3.39) <.001 1.53 (1.17-1.99) .002
Multivariate Analysisa 
Relapse risk 1.06 (0.62-1.81) .85 1.01 (0.70-1.47) .95 1.72 (0.98-3.00) .06 1.15 (0.83-1.59) .39
Overall survival 0.74 (0.27-2.02) .56 1.12 (0.68-1.85) .66 3.03 (1.66-5.53) <.001 1.50 (0.99-2.25) .05
Event-free survival 1.10 (0.68-1.77) .70 1.20 (0.88-1.63) .25 2.04 (1.30-3.22) .002 1.37 (1.05-1.78) .02
Induction deathb  1.12 (0.15-8.45) .91 0.55 (0.13-2.35) .42 1.51 (0.20-11.24) .69 0.70 (0.21-2.35) .92
Death first complete 
remissionb 
0.67 (0.75-2.59) .69 1.63 (0.75-3.59) .22 2.77 (0.84-9.20) .10 2.38 (1.20-4.73) .01
Secondary malignant 
neoplasmb 
3.23 (0.71-14.68) .13 4.66 (1.71-12.64) .003 11.56 (3.18-42.12) <.001 5.95 (2.47-14.37) <.001
Patients aged 2.0-9.9 y
Univariate analysis
Relapse risk 0.64 (0.32-1.30) .21 0.72 (0.43-1.22) .23 0.89 (0.33-2.40) .82 0.75 (0.47-1.21) .25
Overall survival 0.59 (0.19-1.86) .37 1.05 (0.53-2.09) .89 2.06 (0.75-5.61) .16 1.23 (0.69-2.22) .48
Event-free survival 0.80 (0.44-1.39) .40 0.97 (0.64-1.47) .89 1.43 (0.71-2.90) .32 1.05 (0.73-1.52) .77
Multivariate Analysisa 
Relapse risk 0.71 (0.35-1.45) .35 0.71 (0.42-1.20) .20 0.70 (0.26-1.88) .48 0.71 (0.44-1.13) .15
Overall survival 0.69 (0.22-2.20) .53 0.89 (0.45-1.78) .75 1.70 (0.62-4.66) .30 1.05 (0.58-1.88) .88
Event-free survival 0.87 (0.49-1.56) .65 0.93 (0.62-1.41) .75 1.15 (0.57-2.33) .70 0.98 (0.68-1.41) .91
Patients aged 10.0-17.9 y
Univariate analysis
Relapse risk 2.87 (1.21-6.67) .01 1.99 (1.14-3.49) .02 4.81 (2.36-9.79) <.001 2.52 (1.56-4.06) <.001
Overall survival 0.78 (0.11-5.69) .78 1.83 (0.87-3.87) .11 6.24 (2.85-13.66) <.001 2.74 (1.51-4.97) .001
Event-free survival 2.15 (0.93-4.96) .07 2.07 (1.28-3.35) .003 4.67 (2.52-8.66) <.001 2.57 (1.70-3.88) <.001
Multivariate analysisa 
Relapse risk 2.90 (1.24-6.78) .01 1.95 (1.11-3.43) .02 4.32 (2.08-8.97) <.001 2.41 (1.49-3.91) <.001
Overall survival 0.99 (0.13-7.34) .99 1.61 (0.76-3.41) .21 4.91 (2.20-11.05) <.001 2.34 (1.29-4.26) .005
Event-free survival 2.26 (0.98-5.24) .06 1.98 (1.22-3.21) .006 4.00 (2.13-7.54) <.001 2.40 (1.58-3.63) <.001
aThe multivariate analyses are adjusted for age, protocol, risk group and sex. 
bDue to the small number of events, induction death, death in first complete remission and secondary malignant neoplasm in separate age groups 
was not conclusive. 
     |  803EGNELL Et aL.
detect a difference between the different weight categories when 
evaluating how BMI influences response to therapy. However, MRD 
results were available only for the NOPHO 2008 protocol patients, 
decreasing the power of this analysis. The obese and underweight 
patients did not have significantly increased TRM in our study. In 
contrast, a recent study of 373 children with ALL, 58 of whom were 
obese, showed that obese children had worse OS compared to non-
obese likely due to TRM, but there were no association to relapse.25 
In line with other previous studies exploring TRM, BMI in our study 
did not influence the risk of DCR1.9,10,25 The lack of power analyzing 
rare events such as DCR1 and induction death may explain the diffi-
culties in detecting statistically significant differences. The effect of 
BMI at diagnosis on TRM remains controversial in childhood ALL. In 
our study, overweight and obese children had higher risk of second-
ary malignancy. One explanation could be the correlation between 
obesity and cancer driven by the adipose tissue,26 possibly contrib-
uting to an added risk for SMN. Nevertheless, due to small number 
of events, this finding needs to be interpreted with caution.
We also found that older underweight children had a higher re-
lapse risk and a tendency to poorer EFS than those with healthy BMI. 
In den Hoed's cohort,10 underweight patients aged 2-17 years at di-
agnosis had higher risk of relapse. This was observed only in older 
patients in the current study and is of great importance in low- and 
middle-income income countries where underweight is more common. 
However, den Hoed et al similarly found that despite the higher relapse 
rate, the OS of underweight patients did not differ from that of the 
other BMI groups. In the study by the Children's Oncology Group,27 
patients who were underweight or obese and remained in their BMI 
category for more than 50% of the time until maintenance, the risk 
for relapse or death was almost twice as high compared to those with 
normal weight throughout the treatment period; normalization of BMI 
during the same period resulted in decreased risk comparable to never 
being obese or underweight. Unfortunately, we only had the BMI at 
diagnosis and could not compare whether changes in weight during 
therapy are associated with survival outcome. Also, body composition 
changes with therapy with loss of skeletal muscle and increased mus-
cle-associated fat; this may contribute to higher risk of cardiovascular 
and metabolic disorders in adulthood.28,29
While there is a standard BMI cut-off for underweight, over-
weight, and obesity in adults, various cut-offs and references are 
available for children, which may contribute to the conflicting results 
on this topic. A European Childhood Obesity Group guideline30 rec-
ommends using the International Obesity Task Force (IOTF)17 and 
the World Health Organization (WHO)21,31 definitions to assess 
childhood overweight and obesity, and definitions by Cole et al18 and 
the WHO for the prevalence of thinness. In previous studies inves-
tigating the prognostic impact of thinness, overweight, and obesity 
in children with ALL,6,8,9,24,25,27,32 the cut-offs used were those from 
TA B L E  3   Differences in relapse and events according to IOTF BMI category in different age groups
Patients aged 2.0-17.9 y
Total nr of 
events
Underweight 
n = 123 (%)
Healthy weight 
n = 2113 (%)
Overweight 
n = 258 (%)
Obese n = 64 
(%) P value
Relapse 305 14 (11.4) 247 (11.7) 31 (10.0) 13 (20.3) <.001
Deaths 144 4 (2.8) 110 (5.2) 18 (7.0) 12 (18.8) <.001
Induction death 24 1 (0.8) 20 (0.9) 2 (0.8) 1 (1.6)
Death in first complete remission 43 1 (0.8) 31 (1.5) 8 (3.1) 3 (4.7) .05
Secondary malignant neoplasma  22 2 (1.6) 11 (0.5) 6 (2.3) 3 (4.8) <.001
Differences in survival and events according to IOTF BMI category in different age groups
Patients aged 2.0-9.9 y Total nr Underweight 
n = 102 (%)
Healthy weight 
n = 1656 (%)
Overweight 
n = 181 (%)
Obese n = 41 
(%)
P value
Relapse 222 8 (7.8) 195 (11.8) 15 (8.3) 4 (9.8) .35
Deaths 96 3 (2.9) 80 (4.8) 9 (5.0) 4 (9.8) .50
Induction death 19 1 (1.0) 15 (0.9) 2 (1.1) 1 (1.0)
Death in first complete remission 28 1 (1.0) 21 (1.3) 5 (2.8) 1 (2.4) .38
Secondary malignant neoplasm 17 2 (2.0) 10 (0.6) 3 (1.7) 2 (4.9) .01
Patients aged 10.0-17.9 y Total nr Underweight 
n = 21 (%)
Healthy weight 
n = 457 (%)
Overweight 
n = 77 (%)
Obese n = 23 
(%)
P value
Relapse 83 6 (28.6) 52 (11.4) 16 (20.8) 9 (39.1) <.001
Deaths 48 1 (4.8) 30 (6.6) 9 (11.7) 8 (34.8) <.001
Induction death 5 0 5 (1.1) 0 0
Death in first complete remission 15 0 10 (2.2) 3 (3.9) 2 (8.7)
Secondary malignant neoplasm 5 0 1 (0.2) 3 (3.9) 1 (4.3)
Note: P value: Pearson´s chi-square test for distribution of events across BMI weight category.
aSecondary malignant neoplasm: 5 patients developed myelodysplastic syndrome (MDS), 8 acute myeloid leukemia (AML), 8 “other” malignancy and 1 
patient was not specified. 
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nationally representative data for the USA (ie, Centers for Disease 
Control and Prevention). Other studies have categorized BMI using 
SD scores with data from national10 or WHO growth charts.7 These 
differences in methodology make comparison between different 
studies difficult. In addition, we compared obese or overweight/
obese patients with patients with healthy BMI, whereas many stud-
ies have compared obese or overweight patients with the remaining 
patients (ie, underweight and healthy weight patients). Our study 
cohort has fewer children who were overweight and obese than 
earlier studies on the subject. The lower prevalence of overweight 
and obesity in this study is partly attributed to the use of the inter-
national childhood BMI cut-offs by IOTF, which resulted in a lower 
overweight and obesity prevalence compared to when the WHO 
cut-offs were used.30 Furthermore, most studies were conducted 
in the USA, where the incidence of obesity is higher than in north-
ern Europe.33-35 In addition, it is important to note that BMI as an 
anthropomorphic measure, a surrogate for body composition and 
nutritional status, and does not distinguish fat and lean muscle mass 
distribution.
Several hypotheses for biological mechanisms of the effect of 
obesity and underweight on leukemia therapy have been suggested. 
Pharmacokinetics is affected by multiple factors, such as plasma pro-
tein binding capacity, water or lipid solubility of the compound, liver 
metabolism, and the function of the excretion pathway. However, 
studies comparing the pharmacokinetics of various drugs in adult or 
pediatric obese patients with normal weight controls reported con-
flicting results, and few studies have been performed in underweight 
patients.8,9,25,27 A study in St Jude Children's Research Hospital 
F I G U R E  1   Kaplan-Meier curves illustrating the effect of BMI classification on overall survival (A and B) and cumulative incidence 
of relapse (C and D) in younger children (age 2.0-9.9 y) (A and C), and older children (age 10.0-17.9 y) (B and D). For the assessment of 

































































































































     |  805EGNELL Et aL.
found no difference in intracellular levels of thioguanine and meth-
otrexate metabolites or systemic clearance of methotrexate, tenipo-
side, etoposide, and cytarabine between four BMI groups in pediatric 
ALL.9 In vivo and in vitro mice models showed that obesity increased 
the relapse risk after vincristine monotherapy, with the adipocytes 
causing resistance to chemotherapy-induced apoptosis.36 Another 
preclinical study with daunorubicin and vincristine demonstrated 
migration of leukemic blast cells into a protective microenvironment 
in the adipose tissue.37 The findings suggest that migration of leu-
kemic blasts into adipose tissue could contribute to drug resistance 
and, potentially, to relapse. Ehsanipour et al also suggested that adi-
pocytes contributed to a protective leukemia microenvironment due 
to a release of glutamine in the bone marrow, causing leukemia cell 
resistance to asparaginase.38
The mechanisms underlying the association between un-
healthy BMI and ALL outcome are most likely multifactorial. 
Even though our and previous studies show association, there 
may be common underlying predisposing factors rather than di-
rect causality. More studies are needed to determine the under-
lying mechanism behind the impact of obesity, overweight, and 
underweight on survival in patients with ALL. If the increased 
relapse rate is due to toxicity and compromised treatment inten-
sity, treatment modification with personalization of therapy, and 
considering immunological treatment already in first line, could 
be an option. It is also important to highlight that extreme BMI is 
a modifiable prognostic risk factor, and more studies on early in-
terventions (nutrition and physical activity) during treatment are 
needed. A high BMI at the beginning of therapy, as well as weight 
gain during induction, is a strong predictor of overweight and obe-
sity at the end of therapy.39,40 Adequate and appropriate nutrition 
is important and may decrease toxicity and improve quality of life 
and outcome.
In conclusion, our findings confirm that obesity at diagnosis 
is an independent prognostic risk factor in ALL, particularly in 
older children. The mechanisms underlying poorer outcome is yet 
F I G U R E  2   Estimated association between BMI standard 
deviation score (BMI SDS) as a continuous variable in a Cox 
proportional hazards model with restricted cubic splines, in children 
aged 10.0-17.9 y at diagnosis and the log HR for time to relapse. 
The U-shaped association between BMI SDS and log HR of relapse 
show that the risk appears to increase below and above a BMI SDS 
of around zero.
TA B L E  4   Multivariate hazard ratios for relapse, event-free survival and survival according to the WHO BMI cut-offs







Overweight + Obese vs 
Healthy weight P
Patients aged 2-17.9 y
Relapse 1.42 (0.81-2.49) .22 0.91 (0.66-1.26) .58 1.24 (0.78-1.98) .33 1.01 (0.76-1.33) .97
Overall Survival 1.07 (0.39-2.92) .89 1.29 (0.85-1.97) .24 2.13 (1.23-3.67) .007 1.48 (1.03-2.12) .03
Event-free survival 1.33 (0.79-2.24) .28 1.14 (0.88-1.49) .32 1.46 (0.99-2.15) .06 1.21 (0.96-1.52) .11
Induction death 2.02 (0.26-15.52) .50 0.86 (0.29-2.55) .79 0.59 (0.08-4.45) .61 0.79 (0.29-2.15) .64
Death first complete 
remission




2.17 (0.28-16.89) .46 3.14 (1.22-8.11) .02 5.00 (1.38-18.10) .01 3.53 (1.50-8.34) .004
Patients aged 10-17.9 ya 
Relapse 2.41 (1.33-5.11) .02 1.70 (0.95-3.04) .08 3.36 (1.77-6.37) <.001 2.17 (1.35-3.49) .02
Overall survival 1.34 (0.31-5.69) .70 1.96 (0.96-3.99) .06 3.91 (1.81-8.42) <.001 2.46 (1.37-4.43) .003
Event-free survival 1.99 (0.95-4.17) .07 1.96 (1.21-3.18) .006 3.39 (1.95-5.91) <.001 2.35 (1.57-3.53) <.001
Note: Numbers of patients: 77 (3.0%) children were underweight, 1928 (75.4%) healthy weight, 426 (16.7%) overweight and 127 (5.0%) obese.
Adjusted for age, protocol, risk group and sex.
aDue to the small number of events, induction death, death in first complete remission and secondary malignant neoplasm in separate age groups 
was not conclusive. 
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unclear, and our study suggests higher relapse rate as the main 
factor. The increasing prevalence of worldwide overweight and 
obesity41 underlines the need for assessment of its risks in chil-
dren with ALL.
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